IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On July 24, 2017, the board of directors of IRIDEX Corporation (the “Company”) approved the following equity grants to William M. Moore and Atabak Mokari to the terms of the Company’s Amended and Restated 2008 Equity Incentive Plan. Mr. Moore received an award of 15,000 restricted stock units (“RSUs”) and an option to purchase 157,000 shares of the Company’s common stock. Mr. Mokari received an award of 6,000 RSUs and an option to purchase 63,000 shares of the Company’s common stock. RSUs convert into shares of the Company’s common stock on a one-for-one basis. Each RSU and option award is subject to vesting, with one-quarter (1/4) of the shares/units vesting on the one year anniversary of the date of grant and one forty-eighth (1/48) of the total shares/units vesting monthly thereafter.

About IRIDEX CORPORATION (NASDAQ:IRIX)
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.